FUNDING
MMI has received funding from Cycles 2 & 3 of the Programme for Research in Third Level Institutions (PRTLI) as well as from the Health Research Board, Wellcome Trust and the European Union.
KEY AREAS OF RESEARCH
The research portfolio comprises a broad range of genomic, proteomic and transcriptomicbased investigations into four disease areas: A national clinical research infrastructure is being developed to provide an easily accessible means for all those involved in molecular medicine research to come together to develop their skills and broaden their training.
MMI is also providing a national infrastructure for industry (pharma, biotech, diagnostic, medical devices and clinical research organisations) to partner with translational research groups. 
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